Mechanismen der Tumorzelldissemination und Nachweis zirkulierender Tumorzellen beim Urothelkarzinom

Zusammenfassung

Die systemische Aussaat einzelner maligner Zellen aus dem Tumorzellverband stellt einen frühen essentiellen Schritt bei der Metastasierung solider Tumoren dar. Für das Mammakarzinom und andere solide Tumoren konnte gezeigt werden, dass zirkulierende Tumorzellen (CTC) im Blut prognostisch ungünstig sind. In diesem Artikel werden die essentiellen Schritte der Tumorzelldissemination erläutert und die Grundlagen der Tumorzelldetektion dargestellt. Der aktuelle Stand der Wissenschaft bei der Detektion zirkulierender Tumorzellen beim Mamma- und Blasenkarzinom wird erörtert und die potenzielle klinische Bedeutung des Nachweises von CTC beim Blasenkarzinom diskutiert. 

Abstract

Systemic dissemination of single malignant cells from a tumour cell cluster represents an early essential step in the metastastic cascade of solid tumours. Studies in breast cancer and other solid malignancies have shown that the presence of circulating tumour cells (CTC) in the blood is associated with an unfavourable prognosis. In this article the key steps in the course of tumour cell dissemination and the basics of single cell detection are explained. The current literature about single cell detection in carcinoma of the breast and urothelial cancer is reviewed and the potential clinical implications of CTC-detection in bladder cancer are discussed. 

Schlüsselwörter

disseminierte Tumorzellen - zirkulierende Tumorzellen - Mikrometastase - CellSearch

Key words

disseminated tumour cells - circulating tumour cells - micrometastasis - CellSearch

Literatur

• 1 Pantel K, Brakenhoff R H, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells.  Nat Rev Cancer. 2008;  8 329-340
• 2 Lugo T G, Braun S, Cote R J et al. Detection and measurement of occult disease for the prognosis of solid tumors.  J Clin Oncol. 2003;  21 2609-2615
• 3 Mundy G R. Metastasis to bone: causes, consequences and therapeutic opportunities.  Nat Rev Cancer. 2002;  2 584-593
• 4 Gimbrone Jr M A, Cotran R S, Leapman S B et al. Tumor growth and neovascularization: an experimental model using the rabbit cornea.  J Natl Cancer Inst. 1974;  52 413-427
• 5 Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator.  Science. 1991;  251 1451-1455
• 6 Arya M, Bott S R, Shergill I S et al. The metastatic cascade in prostate cancer.  Surg Oncol. 2006;  15 117-128
• 7 Pantel K, Enzmann T, Kollermann J et al. Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation.  Int J Cancer. 1997;  71 521-525
• 8 Riethdorf S, Wikman H, Pantel K. Review: Biological relevance of disseminated tumor cells in cancer patients.  Int J Cancer. 2008;  123 1991-2006
• 9 Pantel K, Brakenhoff R H. Dissecting the metastatic cascade.  Nat Rev Cancer. 2004;  4 448-456
• 10 Morgan T M, Lange P H, Vessella R L. Detection and characterization of circulating and disseminated prostate cancer cells.  Front Biosci. 2007;  12 3000-3009
• 11 Jacob K, Sollier C, Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects.  Expert Rev Proteomics. 2007;  4 741-756
• 12 Riethdorf S, Fritsche H, Muller V et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.  Clin Cancer Res. 2007;  13 920-928
• 13 Allard W J, Matera J, Miller M C et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.  Clin Cancer Res. 2004;  10 6897-6904
• 14 Cristofanilli M, Budd G T, Ellis M J et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer.  N Engl J Med. 2004;  351 781-791
• 15 Hayes D F, Cristofanilli M, Budd G T et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.  Clin Cancer Res. 2006;  12 4218-4224
• 16 Riethdorf S, Muller V, Zhang L et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.  Clin Cancer Res. 2010;  16 2634-2645
• 17 Jiang Y, Palma J F, Agus D B et al. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.  Clin Chem. 2010;  56 1492-1495
• 18 Fehm T, Muller V, Alix-Panabieres C et al. Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance.  Breast Cancer Res. 2008;  10 (S 01) 1
• 19 Budd G T, Cristofanilli M, Ellis M J et al. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.  Clin Cancer Res. 2006;  12 6403-6409
• 20 Fehm T, Muller V, Aktas B et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.  Breast Cancer Res Treat. 2010;  124 403-412
• 21 Retz M, Lehmann J, Roder C et al. Cytokeratin-20 reverse-transcriptase polymerase chain reaction as a new tool for the detection of circulating tumor cells in peripheral blood and bone marrow of bladder cancer patients.  Eur Urol. 2001;  39 516–507 507-515 discussion 516-517
• 22 Gazzaniga P, Gandini O, Giuliani L et al. Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients.  Clin Cancer Res. 2001;  7 577-583
• 23 Kinjo M, Okegawa T, Horie S et al. Detection of circulating MUC7-positive cells by reverse transcription-polymerase chain reaction in bladder cancer patients.  Int J Urol. 2004;  11 38-43
• 24 Osman I, Kang M, Lee A et al. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients.  Int J Cancer. 2004;  111 934-939
• 25 Osman I, Bajorin D F, Sun T T et al. Novel blood biomarkers of human urinary bladder cancer.  Clin Cancer Res. 2006;  12 3374-3380
• 26 Desgrandchamps F, Teren M, Dal Cortivo L et al. The effects of transurethral resection and cystoprostatectomy on dissemination of epithelial cells in the circulation of patients with bladder cancer.  Br J Cancer. 1999;  81 832-834
• 27 Karl A, Tritschler S, Hofmann S et al. Perioperative search for circulating tumor cells in patients undergoing radical cystectomy for bladder cancer.  Eur J Med Res. 2009;  14 487-490
• 28 Naoe M, Ogawa Y, Morita J et al. Detection of circulating urothelial cancer cells in the blood using the CellSearch System.  Cancer. 2007;  109 1439-1445
• 29 Gallagher D J, Milowsky M I, Ishill N et al. Detection of circulating tumor cells in patients with urothelial cancer.  Ann Oncol. 2009;  20 305-308
• 30 Okegawa T, Hayashi K, Hara H et al. Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer.  Int J Urol. 2010;  17 254-258
• 31 Rink M, Chun F K, Minner S et al. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer.  BJU Int. 2010; 
• 32 Retz M, Rotering J, Nawroth R et al. Long-term Follow-up of Bladder Cancer Patients with Disseminated Tumour Cells in Bone Marrow.  Eur Urol. in press DOI: doi:10.1016/j.eururo.2010.12.014
• 33 Gradilone A, Petracca A, Nicolazzo C et al. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer.  BJU Int. 2010;  106 710-715